Novartis AG
remibrutinib
chronic spontaneous urticaria (CSU)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews remibrutinib for chronic spontaneous urticaria (CSU) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 13h ago
“EMA’s CHMP adopted a positive opinion recommending marketing authorization for remibrutinib as an oral treatment for chronic spontaneous urticaria (CSU) in adults with an inadequate response to H1-antihistamine therapy.”